Efficacy and safety of acarbose treatment of NIDDM

Julio Wainstein, Medinah Jedwab

Research output: Contribution to journalArticlepeer-review


An uncontrolled multicenter study of the efficacy and safety of treatment of diabetes with acarbose was conducted on 169 NIDDM patients in 12 medical centers in Israel. Acarbose was administered for 19 weeks, and the patients were followed for an additional 12 weeks. A substantial decrease in HbA(1c) levels from 8.5% to 7.5% (p < 0.001) and in postprandial serum glucose levels from 283.6 mg/dl to 248.5 mg/dl (p < 0.01) was seen during treatment. On follow-up, HbA(1c) levels increased by 0.45% and postprandial serum glucose rebounded from 256.4 mg/dl to 287.9 mg/dl. Acarbose was shown to be effective in treating NIDDM and to be safe and well-tolerated.

Original languageEnglish
Pages (from-to)258-263+311
Issue number4
StatePublished - 16 Feb 1997
Externally publishedYes


Dive into the research topics of 'Efficacy and safety of acarbose treatment of NIDDM'. Together they form a unique fingerprint.

Cite this